



Product Introduction

TG101209

TG101209 is a selective **JAK2** inhibitor with **IC50** of 6 nM, less potent to Flt3 and RET with IC50 of 25 nM and 17 nM, ~30-fold selective for JAK2 than JAK3, sensitive to JAK2V617F and MPLW515L/K mutations.

Technical Data:

Molecular Weight (MW):	509.67	 <chem>CC1(C)C(C)C1S(=O)(=O)Nc2cc(Nc3nc4c(ncn4C)c3)ccc(Nc5ccc(N6CCN(C)CC6)cc5)c2</chem>
Formula:	C ₂₆ H ₃₅ N ₇ O ₂ S	
Solubility (25°C)	DMSO 102 mg/mL	
* <1 mg/ml means slightly soluble or insoluble:	Water <1 mg/mL	
	Ethanol <1 mg/mL	
Purity:	>98%	
Storage:	3 years -20°C Powder 6 months-80°C in DMSO	
CAS No.:	936091-14-4	

Biological Activity

TG101209 is an orally bioavailable, small molecule, ATP-competitive inhibitor towards several tyrosine kinases. TG101209 inhibits growth of Ba/F3 cells expressing JAK2V617F or MPLW515L mutations with an IC50 of 200 nM. In a human JAK2V617F-expressing acute myeloid leukemia cell line, TG101209 induces cell cycle arrest and apoptosis, and inhibits phosphorylation of JAK2V617F, STAT5 and STAT3. TG101209 suppresses growth of hematopoietic colonies from primary progenitor cells harboring JAK2V617F or MPL515 mutations. ^[1] TG101209 significantly reduces STAT5 phosphorylation without affecting the total

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

amount of STAT5 protein. [2] TG101209 inhibits survivin and reduces phosphorylation of STAT3 in HCC2429 and H460 lung cancer cells. TG101209 results in radio sensitization of HCC2429 and H460 lung cancer cells in vitro. [3] A recent study indicates TG101209 abrogates BCR-JAK2 and STAT5 phosphorylation, decreases Bcl-xL expression and triggered apoptosis of transformed Ba/F3 cells. [4] 100 mg/kg of TG101209 effectively prolongs the survival in JAK2V617F-induced disease (10 days). Compared with placebo-treated animals, TG101209-treated animals exhibit statistically significant, dose-dependent reduction in the circulating tumor cell burden at day +11 to 20%. [1]

References

- [1] Pardanani A, et al, *Leukemia*, 2007, 21(8), 1658-1668.
- [2] Ma AC, et al, *Exp Hematol*, 2009, 37(12), 1379-1386.
- [3] Sun Y, et al, *J Thorac Oncol*, 2011, 6(4), 699-706.
- [4] Cuesta-Dominquez A, et al, *PLoS One*, 2012, 7(2), e32451.
- [5] Wang Y, et al, *Blood*, 2009, 114(24), 5024-5033.



Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.